Adlai Nortye (ANL) Competitors $2.35 +0.09 (+3.98%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends ANL vs. ATYR, TERN, TRML, CYRX, ACB, ATAI, GOSS, FHTX, ANNX, and NMRAShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Atyr PHARMA (ATYR), Terns Pharmaceuticals (TERN), Tourmaline Bio (TRML), Cryoport (CYRX), Aurora Cannabis (ACB), Atai Life Sciences (ATAI), Gossamer Bio (GOSS), Foghorn Therapeutics (FHTX), Annexon (ANNX), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Atyr PHARMA Terns Pharmaceuticals Tourmaline Bio Cryoport Aurora Cannabis Atai Life Sciences Gossamer Bio Foghorn Therapeutics Annexon Neumora Therapeutics Adlai Nortye (NASDAQ:ANL) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership. Do insiders and institutionals have more ownership in ANL or ATYR? 35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 3.7% of Atyr PHARMA shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate ANL or ATYR? Adlai Nortye presently has a consensus price target of $9.00, indicating a potential upside of 291.30%. Atyr PHARMA has a consensus price target of $18.60, indicating a potential upside of 463.64%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Is ANL or ATYR more profitable? Adlai Nortye's return on equity of 0.00% beat Atyr PHARMA's return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Atyr PHARMA N/A -79.44%-59.16% Which has more risk & volatility, ANL or ATYR? Adlai Nortye has a beta of -1.42, indicating that its share price is 242% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Does the MarketBeat Community believe in ANL or ATYR? Atyr PHARMA received 4 more outperform votes than Adlai Nortye when rated by MarketBeat users. CompanyUnderperformOutperformAdlai NortyeOutperform Votes8100.00% Underperform VotesNo VotesAtyr PHARMAOutperform Votes12100.00% Underperform VotesNo Votes Does the media refer more to ANL or ATYR? In the previous week, Adlai Nortye had 1 more articles in the media than Atyr PHARMA. MarketBeat recorded 2 mentions for Adlai Nortye and 1 mentions for Atyr PHARMA. Adlai Nortye's average media sentiment score of 1.44 beat Atyr PHARMA's score of 0.94 indicating that Adlai Nortye is being referred to more favorably in the media. Company Overall Sentiment Adlai Nortye Positive Atyr PHARMA Positive Which has stronger earnings and valuation, ANL or ATYR? Atyr PHARMA has lower revenue, but higher earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M16.97-$104.87MN/AN/AAtyr PHARMA$235K1,178.76-$50.39M-$0.94-3.51 SummaryAtyr PHARMA beats Adlai Nortye on 10 of the 15 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.87M$7.21B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E RatioN/A6.1524.9519.24Price / Sales16.97187.68375.54110.22Price / CashN/A65.6738.0534.58Price / BookN/A6.447.334.28Net Income-$104.87M$139.03M$3.18B$247.04M7 Day Performance3.60%-5.52%-4.42%-4.36%1 Month Performance10.05%-8.56%-6.07%-5.60%1 Year Performance-70.89%-14.59%11.42%3.38% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye2.7692 of 5 stars$2.30+1.8%$9.00+291.3%-71.4%$84.87M$5M0.00127Short Interest ↓Positive NewsGap UpHigh Trading VolumeATYRAtyr PHARMA2.6801 of 5 stars$3.83-11.3%$18.60+385.6%N/A$321.49M$350,000.00-4.0753TERNTerns Pharmaceuticals4.5943 of 5 stars$3.73-7.0%$18.30+390.6%-49.5%$316.83MN/A-3.1640Analyst ForecastTRMLTourmaline Bio2.4309 of 5 stars$12.25+0.3%$54.67+346.3%-69.3%$314.13MN/A-4.3444Gap UpCYRXCryoport2.1623 of 5 stars$6.33+1.8%$12.29+94.1%-68.9%$312.90M$226.11M-1.871,170News CoverageACBAurora Cannabis1.2709 of 5 stars$5.61-4.8%N/A+60.9%$307.75M$320.81M112.221,073Positive NewsATAIAtai Life Sciences3.1265 of 5 stars$1.82-8.5%$9.00+394.5%-19.2%$305.40M$331,000.00-2.2580GOSSGossamer Bio4.2966 of 5 stars$1.30-7.1%$9.20+607.7%-10.9%$294.58MN/A-4.06180News CoverageGap UpFHTXFoghorn Therapeutics2.354 of 5 stars$5.16-1.3%$13.17+155.2%-38.9%$286.95M$34.15M-2.69120Positive NewsANNXAnnexon1.8616 of 5 stars$2.65-5.7%$15.80+496.2%-55.8%$282.46MN/A-2.5260Earnings ReportNews CoverageNMRANeumora Therapeutics3.7073 of 5 stars$1.71-5.0%$16.50+864.9%-91.4%$276.27MN/A-0.91108Earnings ReportUpcoming EarningsGap Up Related Companies and Tools Related Companies Atyr PHARMA Alternatives Terns Pharmaceuticals Alternatives Tourmaline Bio Alternatives Cryoport Alternatives Aurora Cannabis Alternatives Atai Life Sciences Alternatives Gossamer Bio Alternatives Foghorn Therapeutics Alternatives Annexon Alternatives Neumora Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANL) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
